Chairman & CEO, Organovo
Keith Murphy is Chairman and Chief Executive Officer at Organovo. Murphy has more than 20 years of experience in biotechnology, including co-founding Organovo in 2007 and serving in Product Strategy and Director of Process Development roles at Amgen. His ten years at Amgen included four years as Global Operations Leader for the largest development program in Amgen’s history, Phase 3 osteoporosis/bone cancer drug denosumab. At Amgen, he also worked to develop several other novel formulation and device products. Prior to Amgen, he played a central role at Alkermes, Inc. on the development team for their first approved product, Nutropin (hGH) Depot. He holds a B.S. in chemical engineering from the Massachusetts Institute of Technology and is an alumnus of the UCLA Anderson School of Management.Prior to 1992, Milner was as an assistant professor of medicine at Washington University in St. Louis. His research led to the discovery of pleiotrophin (PTN), a novel growth factor that regulates stem cell differentiation, organ development, and the epithelial mesenchymal transition (EMT). He was educated at the University of Liverpool receiving his medical degree in 1980, before completing his postgraduate training at the Johns Hopkins Hospital, the University of Virginia and Washington University in St. Louis. Milner is co-inventor on 50 issued patents, and an author of 29 original scientific articles in science, biochemistry, circulation, cancer, JCI and JBC. He is a fellow of the American College of Cardiology (FACC), and a board certified physician and cardiologist. He also serves as adjunct clinical faculty at Stanford University School of Medicine.